Iain Fraser, MBChB, D.Phil was appointed Interim CMO, effective March 9, 2023. He most recently served as Vice President and Clinical Fellow at AlloVir, an Elevate Bio Company.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
- Fulcrum Therapeutics downgraded at Morgan Stanley on clinical hold uncertainty
- Fulcrum Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
- Fulcrum Therapeutics price target lowered to $20 from $26 at Oppenheimer
- Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
